All
Checkpoint Inhibitor Therapy and ISRT Maintains Outcomes in Younger Patients With cHL
Replacing transplant and chemo with CI-based therapy and ISRT maintains survival, reduces side effects in younger patients with classic Hodgkin lymphoma.
FDA Approves Tevimbra Plus Chemotherapy For Some With Esophageal Cancer
The FDA approved Tevimbra with chemotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1.
Expert Explains Safety of Krazati Regimen For Treating Colorectal Cancer
Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and less immune suppression.
Immune Checkpoint Inhibitors For Cancer Associated With Psoriasis Risk
Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a risk of new onset psoriasis.
Primary Central Nervous System Lymphoma Patient and Care Partner Roundtable Hosted by the End Brain Cancer Initiative
Accepting My Colon Cancer Diagnosis at A Young Age
Being diagnosed with colon cancer at 34 was difficult, but choosing happiness and acceptance helped me find peace through mindfulness, nature and family.
Rusfertide Elicits Promising Responses in Polycythemia Vera
Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted in positive responses.
FDA Accepts Ordspono Resubmission in R/R Follicular Lymphoma Treatment
The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.
My Journey With Squamous Cell Carcinoma
A patient shares his experience with a squamous cell carcinoma diagnosis, treatment and recovery.
First Patient With Small Cell Lung Cancer Dosed With Peluntamig
The first patient with small cell lung cancer has been dosed in a trial of peluntamig (PT217) combined with chemotherapy.
First Patient Dosed With HLD-0915 for mCRPC in First-In-Human Trial
The first patient has been dosed in a first-in-human clinical trial evaluating HLD-0915 for metastatic castration-resistant prostate cancer.
Breaking Down The Results of The ALPHA/ALPHA2 Study in Large B-Cell Lymphoma
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Camizestrant Combo Improves Progression Time in HR+/HER2– Breast Cancer
Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in HR+/HER2– advanced breast cancer.
Cema-Cel Has Durable Responses in in Relapsed/Refractory Large B-Cell Lymphoma
Treatment with the CAR T-cell therapy cema-cel demonstrated durable responses in patients with relapsed/refractory large B-cell lymphoma.
Chemoradiation Benefits for Cervical Cancer May Decline After Age 80
Chemoradiation improves survival in cervical cancer patients, but benefits may decline after age 80, according to a study using SEER data.
A Second Chance I Never Knew I Had After Lymphoma
A year ago, I was told my lymphoma had worsened, but a miraculous turn of events spared me from aggressive chemotherapy, making me grateful for each day of life.
An Expert Highlights His Key Takeaways From The 2025 ASCO GU Symposium
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Pregnancy After Glioma Diagnosis Associated With Worse Progression Time
For female patients with glioma, pregnancy after receiving a diagnosis of glioma is associated with worse progression-free survival times.
There is a Growing Need For Genetic Testing and Precision Medicine in GU Cancers
Dr. Chandler Park helps patients with genitourinary cancers, including both prostate and bladder, understand the importance of genetic testing.
Fractionated Reirradiation is Safe and Feasible in High-Grade Glioma
Fractionated reirradiation is safe and feasible, suggesting higher reirradiation dose may be feasible in patients with recurrent high-grade glioma.
ctDNA Alone ‘Not Sufficient’ When Monitoring Patients With Colorectal Cancer
The addition of ctDNA testing to radiographic surveillance resulted in curative surgical intervention for 1.6% of patients with colorectal cancer.
My Cousin and I Journey Through Breast, Lung, Pancreatic and Prostate Cancer
After realizing that a stronger support system would have helped me emotionally and spiritually in my cancer journey, I committed myself to being there for my cousin.
Datroway May Be Effective in Non-Small Cell Lung Cancer Subtypes
Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic alterations, including EGFR and ALK subgroups.
Moving Beyond Chemotherapy: How Biomarker Testing is Changing Cancer Care
Metronomic Capecitabine and an AI Improve Survival in HR+/HER2– Metastatic Breast Cancer
Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative metastatic breast cancer.
Off-The-Shelf CAR T Therapy Elicits Responses in Large B-Cell Lymphoma
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
A Study Investigates If CAR T Therapy Directly Causes Secondary Malignancies
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
The Bittersweet Blessings of Being a Young Adult Cancer Survivor
Being a young adult cancer survivor is bittersweet, bringing both unique struggles and unexpected blessings that shape my life, career and perspective.
Minimal Residual Disease Testing’s Variability Across Cancer Types
Dr. Christopher R. Flowers explains that MRD testing varies by cancer type, with results impacting recurrence risk and monitoring based on disease characteristics.
What Patients With Breast Cancer Need to Know About Itovebi and Blood Sugar
An expert explained a potential side effect associated with treatment consisting of Itovebi for breast cancer.
